Herbalife Q2: 5.4% Sales Growth Looks Fine-EBITDA Cuts Are the Real Warning

Herbalife grew sales, but investors are focused on profit conversion

Herbalife posted Q2 net sales of $1.3 billion, up 5.4% year-over-year and marking the fourth consecutive quarter of year-over-year net sales growth. The top line is not the problem; the question is whether that demand is turning into durable earnings.

Why this quarter matters

Management said Q2 results were at the high end of previously issued guidance. At the same time, profitability came under pressure. That is why the focus has shifted from growth alone to the quality of that growth.

The market's read: growth is fine, margins are the test

Bulls can point to strong execution: constant currency sales grew 5.8%, and management said the constant currency outlook remains consistent even with stronger-dollar headwinds for reported numbers.

Bears will focus on the gap between sales growth and earnings capture. Adjusted earnings of $0.51 per share missed Wall Street expectations of $0.63, sending shares down 2.78%, while China net sales fell 24.5% year over year and EMEA declined 3.5%. The takeaway is straightforward: demand looks reasonable, but the mix and currency are making reported profits harder to keep.

Regional mix is now the main pressure on margins

The four-quarter sales streak has improved Herbalife's credibility. What it has not resolved is why growth is offering less protection for profits than it may have in the past.

North America stabilized, but the growth burden shifted

North America was barely moving at 0.2% improvement. Meanwhile, Latin America delivered its fourth consecutive quarter of double-digit growth, with reported sales up 16.6%, and Asia Pacific added reported sales growth of 15.2%. That helped drive overall growth, but it came alongside EMEA declined 3.5% and China net sales fell 24.5% year-over-year.

That mix matters because weaker markets dilute the benefit that fixed costs otherwise get from higher volume. In other words, this looks less like a collapse in demand and more like a tougher blend of markets.

What investors need to see next

The core debate now is simple: can Herbalife hold margins while the geographic mix stays uneven? For now, the cleaner way to read the quarter is to separate underlying demand from reported pressure caused by currency and mix.

The new product stack has to do more than add revenue

One bridge point: this quarter is no longer about whether Herbalife can sell. It is about whether the newer product ecosystem can improve the gap between revenue growth and earnings capture.

Why the gap matters

Management said Q2 was at the high end of previously issued guidance, with fourth consecutive quarter of year-over-year net sales growth, yet profitability came under pressure. That spread is the real watchpoint. If new launches only add volume, the stock may stay trapped in a growth-with-thin-cushion setup. If they improve pricing resilience and customer economics, the market may treat the business differently.

The rerating case is now a mix-quality story

Herbalife is still expanding Bioniq GO... across 11 EMEA markets and North America, introducing new solutions under its Life I/O healthy lifespan brand, and adding digital tools such as at-home blood biomarker diagnostics for select distributors in North America. If those initiatives shift the business toward higher-value offerings, they could help offset weaker performance in mature or struggling markets.

If not, sales growth may continue to look fine while profits remain pinched.